TY -的T1 bedaquiline对治疗结果的影响的耐多药结核病高负担国家JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02544 -2020欧元六世- 57 - 6 SP - 2002544 AU Chesov Dumitru盟——Heyckendorf Jan AU - Alexandru索非亚盟多,安娜盟——Chesov Elena盟——Reimann Maja盟——Crudu Valeriu盟——Botnaru维克多AU -兰格,Christoph Y1 - 2021/06/01 UR - //www.qdcxjkg.com/content/57/6/2002544.abstract N2 -背景评估新型抗结核治疗耐多药结核病药物(MDR)一样,仍然是高利息的结核病研究议程。我们评估肺耐多药结核病患者的治疗结果接受bedaquiline-containing治疗方案在摩尔多瓦共和国,一个耐多药结核病高负担国家。方法我们系统地分析了SIMETB国家结核病电子数据库和执行回顾倾向score-matched比较治疗结果在一群耐多药结核病患者开始治疗2016 - 2018年期间bedaquiline-containing方案(bedaquiline队列)和一群患者没有bedaquiline (non-bedaquiline队列)。结果倾向得分匹配后,114名患者被分配到每个群耐多药结核病患者。bedaquiline队列中的患者6个月痰培养较高转化率比non-bedaquiline队列(分别为66.7%和40.3%;术中,0.001)。病人在bedaquiline-containing方案有较高的治愈率评估由世界卫生组织(世卫组织)和TBnet定义(分别为55.3%和24.6%;p = 0.001和43.5%和19.6%;分别为p = 0.004),以及更低的死亡率(分别为8.8%和20.2%;术;10.9%和0.001和25.2%;分别为p = 0.01)。 In patients who previously failed on MDR-TB treatment, >40% of patients achieved a cure with a bedaquiline-containing regimen.Conclusions Bedaquiline-based MDR-TB treatment regimens result in better disease resolution when compared with bedaquiline-sparing MDR-TB treatment regimens under programmatic conditions in a country with a high burden of MDR-TB.Used under programmatic conditions in a high-burden MDR-TB setting, bedaquiline-based MDR-TB treatment regimens result in faster and more sustained disease resolution than bedaquiline-sparing MDR-TB treatment regimens https://bit.ly/37mSQOT ER -